Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in HIV-Infected Adults

被引:14
作者
DiCenzo, Robert [1 ,2 ]
DiFrancesco, Robin [3 ]
Cruttenden, Kim
Donnelly, Julie [3 ]
Schifitto, Giovanni
机构
[1] St John Fisher Coll, Wegmans Sch Pharm, Rochester, NY 14618 USA
[2] Univ Rochester, Med Ctr, Div Infect Dis, Rochester, NY 14627 USA
[3] SUNY Buffalo, Buffalo, NY 14260 USA
基金
美国国家卫生研究院;
关键词
cerebrospinal fluid; HIV; lopinavir; pharmacokinetics; trough concentration; IMMUNODEFICIENCY-VIRUS TYPE-1; TANDEM MASS-SPECTROMETRY; POPULATION PHARMACOKINETICS; PROTEASE INHIBITORS; P-GLYCOPROTEIN; PENETRATION; PLASMA; INDINAVIR; ZIDOVUDINE; LAMIVUDINE;
D O I
10.1345/aph.1M399
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: The central nervous system may act as a sanctuary site for viral replication in the setting of low antiretroviral penetration. Data on lopinavir cerebrospinal fluid (CSF) trough concentration (C-trough) values have yet to be reported. OBJECTIVE: To describe lopinavir CSF C-trough values and compare them with a measure of HIV susceptibility. METHODS: In a prospective, open-label design, HIV-infected adults whose regimen included lopinavir/ritonavir 400/100-mg soft-gel capsules twice daily for at least 4 weeks were enrolled. Each subject had 8 plasma lopinavir concentrations determined over a 12-hour dosing interval and 1 CSF lopinavir C-trough value determined at the end of the study. Linear regression methods tested for associations between CSF or CSF to plasma concentration ratio and covariates including pharmacokinetic parameters and CSF protein. RESULTS: Ten patients (7 male; median [range] +/- SD age 45.3 +/- 2.8 y) completed the study. Median (intraquartile range [IQR]) lopinavir plasma 0- to 12-hour area under the curve (AUC(0-12)) and minimum concentrations were 71.3 h.mu g/mL (48.4-87.6) and 3.82 mu g/mL (2.76-5.34). Median (IQR) CSF C-trough, paired plasma concentration, and time since last dose were 11,200 pg/mL (6760-16,400), 5.42 mu g/mL (3.88-5.85), and 9.9 hours (9.7-10.2), respectively. Median (IQR) CSF to plasma concentration ratio was 0.225% (0.194-0.324). Lopinavir CSF C-trough was above the median 50% inhibitory concentration (IC50) for wildtype HIV-1 (wtHIV-1) (1900 pg/mL) in all subjects. Lopinavir plasma AUC(0-12) (r(2) = 0.65; p = 0.009) and CSF protein (r(2) = 0.26; p = 0.006) were associated with lopinavir CSF concentration, while CSF protein (r(2) = 0.66; p = 0.008) was associated with CSF to plasma concentration ratio. CONCLUSIONS: Lopinavir CSF C-trough was above the median IC50 for wtHIV-1 replication in all patients receiving lopinavir/ritonavir 400/100-mg soft-gel capsules twice daily.
引用
收藏
页码:1972 / 1977
页数:6
相关论文
共 19 条
[1]  
*ABB LAB, 2007, PRESCR INF KAL LOP
[2]   PENETRATION OF ZIDOVUDINE INTO THE CEREBROSPINAL-FLUID OF PATIENTS INFECTED WITH HIV [J].
BURGER, DM ;
KRAAIJEVELD, CL ;
MEENHORST, PL ;
MULDER, JW ;
KOKS, CHW ;
BULT, A ;
BEIJNEN, JH .
AIDS, 1993, 7 (12) :1581-1587
[3]   Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV [J].
Capparelli, EV ;
Holland, D ;
Okamoto, C ;
Gragg, B ;
Durelle, J ;
Marquie-Beck, J ;
van den Brande, G ;
Ellis, R ;
Letendre, S .
AIDS, 2005, 19 (09) :949-952
[4]   Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid [J].
Capparelli, EV ;
Letendre, SL ;
Ellis, RJ ;
Patel, P ;
Holland, D ;
McCutchan, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2504-2506
[5]   Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry [J].
DiFrancesco, Robin ;
DiCenzo, Robert ;
Vicente, Glorimar ;
Donnelly, Julie ;
Martin, Troy M. ;
Colon, Luis A. ;
Schifito, Giovanni ;
Morse, Gene D. .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2007, 44 (05) :1139-1146
[6]   Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry [J].
Frerichs, VA ;
DiFrancesco, R ;
Morse, GD .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 787 (02) :393-403
[7]  
Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69
[8]   Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins [J].
Gimenez, F ;
Fernandez, C ;
Mabondzo, A .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (02) :649-658
[9]   Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection [J].
Haas, DW ;
Stone, J ;
Clough, LA ;
Johnson, B ;
Spearman, P ;
Harris, VL ;
Nicotera, J ;
Johnson, RH ;
Raffanti, S ;
Zhong, L ;
Bergqwist, P ;
Chamberlin, S ;
Hoagland, V ;
Ju, WD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (04) :367-374
[10]   Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma [J].
Haas, DW ;
Johnson, B ;
Nicotera, J ;
Bailey, VL ;
Harris, VL ;
Bowles, FB ;
Raffanti, S ;
Schranz, J ;
Finn, TS ;
Saah, AJ ;
Stone, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2131-2137